These data further strengthen the validity of our ChIP-Seq findings and also highlight the need to identify targets of Olig2 in vivo, as many of the downstream effector targets of Olig2 under normal conditions are likely involved in variety of pathophysiological events including cancer. The gene discussed is OLIG2; the disease is cancer.